Most frequent mutational events of home box 13 gene in prostatic adenocarcinoma and correlation with tumor characteristics

Publication date: Available online 15 November 2019Source: Meta GeneAuthor(s): Berjas Abumsimir, Mohammed Mrabti, Abdelilah Laraqui, Ahmed Ameur, Saad Ibnsouda Koraishi, Mohammed Mzibrie, Mohammed Nabil Benchekroun, Hlima Bessi, Ikram Tiabi, Ihsan Almahasneh, Moulay Mustapha EnnajiAbstractThe home box transcription factor gene (HOXB13) plays a certain role in human development and prostate tumorgenesis. Genetic alterations of HOXB13 help to explore the suspected role in prostate cancer. To determine the prevalence and clinical correlates of high-frequent mutational events in home box transcription factor (HOXB13); DNA samples from 50 men treated at the military hospital in Rabat, Morocco, were genotyped and confirmed by Sanger sequencing. The frequency and distribution of high frequent mutations were determined according to patient pathological characteristics. Within coding region of HOXB13; the Frameshift mutation: c.575delG (p.Gly192Valfs) with frequency of 5/50 (10%), and nonsense mutation: c.261C > A (p.Tyr87Ter), frequency: 6/50 (12%) and Missense mutations: c.665C > G (p.Pro222Arg), c.643C > T (p.Arg215Cys), c.776A > C (p.Gln259Pro), c.757A > C (p.Thr253Pro) with frequency rates: 10/50 (20%), 9/50 (18%), 8/50 (16%), and 7/50 (14%) respectively, were the most frequent mutations. Patients carrying one or more high frequent mutation at the same time treated with radical prostatectomy were: 9/35(26%), and 8/35 (23%) of them have pathologi...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research

Related Links:

AbstractSimple prostatectomy is an option for management of patients with enlarged prostates and obstructive symptoms. However, the guidelines still do not state a gold-standard treatment for men with BPH and some of these patients with BPH are also known to harbor prostate cancer. This issue can be a challenge because, in the traditional simple prostatectomy, the prostate capsule is often left in place, and that is usually the area of the prostate cancers. With the robotic approach, our goal is to analyze the outcomes of modified simple prostatectomy (MSP) by the elimination of the entire prostate tissue. Thirty-four pati...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Metastasis of prostate cancer (PCa) to renal pelvis is extremely rare. A 64-year-old man was hospitalized for increased prostate specific antigen (PSA) after radical prostatectomy. 68Ga-PSMA-11 PET/CT showed hydronephrosis caused by a mass in the left renal pelvis without significant uptake of PSMA tracer. The histopathology indicated metastatic PCa with a Gleason score of 5+5 but negative for prostate specific membrane antigen (PSMA) following nephroureterectomy. Although metastasis to renal pelvis is rare, the occurrence possibility could not be ignored when with hydronephrosis is found in prostate cancer patients.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
We report these paired primary epithelial cultures under CRC growth as a potentially useful tool for studies to understand molecular mechanisms underlying health disparities in prostate cancer. PMID: 31576543 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
We report for the first time, a minimally invasive technique that avoids the need of VUA with favorable functional results.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Condition:   Prostatic Adenocarcinoma Intervention:   Sponsor:   University Hospital, Brest Recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Non-metastatic Prostate Cancer;   Prostate Adenocarcinoma Interventions:   Procedure: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy];   Procedure: Focal therapy;   Procedure: Focal therapy after Finasteride 5Mg tablets for 12 weeks;   Procedure: Focal therapy after Bicalutamide 50Mg tablets for 12 weeks Sponsors:   Imperial College London;   Prostate Cancer UK;   Imperial Clinical Trials Unit (ICTU) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Hospitals | Morocco Health | Prostate Cancer | Prostatectomy